Peripheral Arterial Disease Clinical Trial
Official title:
Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease
Peripheral arterial disease (PAD) is a common condition that arises due to the build up of
atheroma in the arteries supplying blood to the peripheral muscles and other tissues. This
imbalance between oxygen supply and demand becomes particularly apparent when patients with
the condition are walking. The pain and weakness they experience (mainly in the calf but
less commonly in the thigh) is known as intermittent claudication and resolves upon
cessation of exercise.
It is an important disease to study as it is (i) common (est. prevalence of symptomatic
intermittent claudication in Scotland of 4.5%) and (ii) those with it have a 1.6 times
higher relative risk of ischaemic heart disease. These patients also have a significantly
higher mortality than age-matched controls at around 12% per year.
There are two main aims of therapy - (i) to reduce the risk of cardiovascular events by way
of standard secondary prevention measures (smoking cessation, anti-platelet,
anti-hypertensive and cholesterol-lowering therapy, diabetic control) and (ii) to treat
symptoms.
Supervised exercise therapy has been shown to be beneficial in improving walking time and
distance in selected patients with leg pain from intermittent claudication with an overall
increase in walking distance of approximately 150 metres at three months.
There are numerous drug treatments available for consideration in PAD patients (mainly
cilostazol in the UK), but many of these have either undesirable side effects or no clear
evidence of benefit. The range of increase in walking distance on cilostazol was reported to
be a 50-76% increase over three months compared to 20% with placebo with some significant
improvements in Quality of Life (QOL) indicators, although with a significant number of
adverse effects (16% vs 8% on placebo) limiting therapy. The current cost (March 2010) is
£35.31/month.
Other options for therapy include angioplasty and bypass surgery. At present these are only
recommended for patients who fail to respond to medical therapy and have severely disabling
symptoms (in the absence of significant exercise-limiting comorbidities).
The investigators will recruit 50 patients with peripheral arterial disease for a
randomised, double-blind, placebo-controlled parallel group study to see if allopurinol
prolongs time to leg pain and maximum walking distance as assessed by treadmill testing and
the six minute walk test. Recruitment will take place in Dundee, i.e. a single-centre trial.
Treatment will last for 24 weeks.
Participants will be recruited from current and past attendees at the vascular laboratory
and both the intermittent claudication clinic and other outpatient clinics at Ninewells.
Participants will be allowed to continue all their usual medication throughout. After two
baseline treadmill tests, they will be randomised to either allopurinol or placebo in a
parallel group study and in a double blind fashion. Each participant will be on-study for 24
weeks (which is the standard time for all PAD medical intervention trials). The ultimate
dose of allopurinol will be 300 mg BD, which is the dose known to work in angina. However,
for safety purposes, the initial dose will be 100 mg/day for two weeks, rising to 300 mg/day
for four weeks, followed by 600 mg/day for the next 18 weeks. Participants and their bloods
(UE, LFT, FBC) will be monitored at weeks 0, 6, 18 and 24 weeks and medication stopped or
reduced in dose if concerns arise. If study drug dose is reduced, they will stay in study.
If study drug needs to be stopped, they will stay in study in order to do an "intention to
treat" analysis.
Double blind medication (allopurinol or placebo) will be prepared and packaged by Tayside
Pharmaceuticals. The medication will come labelled as "Participant 1", "Participant 2", etc.
and will be distributed to the participant by the research fellow according to their
sequence number. The blinded treatment code will be kept by the Clinical Trials Pharmacy
Department, Ninewells, who operate a 24 hour emergency unblinding facility (as necessary)
and in a sealed envelope in a locked fireproof cabinet accessible by a responsible member of
University of Dundee staff not directly involved in the study.
The following is the programme of visits involved in this study (list taken from the
participant information sheet) -
- Visit 1 (week 0) - screening visit 1
- Consent - answer any outstanding questions you may have and complete the consent
form.
- Measurement of blood pressure in arms and legs
- Treadmill test
- Blood samples
- Visit 2 (week 0) - screening visit 2
- Treadmill test - if this is stable and similar to the previous test then you are
able to continue in the study
- Six minute walk test
- Measurement of blood vessel 'stiffness'
- Supply of initial study medication along with instructions.
- Two questionnaires - Walking Impairment and Quality of Life
- Visit 3 (week 6) - progress visit
- Check how you are doing on the medications
- Blood samples
- Supply of study medication for the remainder of the study
- Visit 4 (week 12) - progress visit
- Treadmill test
- Six minute walk test
- Check how you are doing on the medications
- Two questionnaires - Walking Impairment and Quality of Life
- Visit 5 (week 18) - progress visit
- Measurement of blood vessel 'stiffness'
- Check how you are doing on the medications
- Blood samples
- Visit 6 (week 24) - final visit
- Measurement of blood vessel 'stiffness'
- Treadmill test
- Six minute walk test
- Measurement of blood pressure in arms and legs
- Check how you are doing on the medications
- Blood samples
- Two questionnaires - Walking Impairment and Quality of Life
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |